EU Imposes Landmark CBD Safety Cap, Raising Stakes for Supplement Industry

EFSA introduces sharply lower intake threshold, raising questions for the future of CBD supplements in Europe

The European Union has taken a major step in regulating cannabidiol (CBD), setting its first provisional daily safety limit under the Novel Food Regulation. The European Food Safety Authority (EFSA) announced that highly purified CBD should not exceed 0.0275 milligrams per kilogram of body weight per day. For an average 70 kg adult, that equals roughly 2 milligrams daily, far lower than previous recommendations in some countries.

This new limit applies only to CBD isolates with at least 98% purity, free from nanoparticles, and produced through verified safe processes. It does not apply to pregnant or breastfeeding women, people under 25, or individuals taking medications, as EFSA says safety cannot yet be confirmed for these groups.

In its statement, EFSA’s Panel on Nutrition, Novel Foods and Food Allergens noted that “the safety of CBD for individuals under 25 years of age, pregnant or lactating women, and those on concurrent medications cannot be established.” The agency highlighted concerns about potential liver effects, developmental risks, and interactions with other drugs.

The ruling follows EFSA’s 2022 decision to pause CBD approvals due to limited safety data. While research has advanced, uncertainties remain, particularly around long-term use and neurological development.

The new threshold could significantly impact CBD products sold across Europe, especially those marketed for relaxation and stress relief. Companies may now need to reformulate or relabel products to meet stricter EU standards.

As global regulators continue to take varied approaches to CBD, the EU’s decision signals a more cautious and science-driven path forward for the fast-growing wellness market.